These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 8974587)

  • 1. [Transport of the hexapeptide dalargin across the hemato-encephalic barrier into the brain using polymer nanoparticles].
    Aliautdin RN; Petrov VE; Ivanov AA; Kreuter J; Kharkevich DA
    Eksp Klin Farmakol; 1996; 59(3):57-60. PubMed ID: 8974587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles).
    Kreuter J; Alyautdin RN; Kharkevich DA; Ivanov AA
    Brain Res; 1995 Mar; 674(1):171-4. PubMed ID: 7773690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoparticles, a drug carrier system to pass the blood-brain barrier, permit central analgesic effects of i.v. dalargin injections.
    Schröder U; Sabel BA
    Brain Res; 1996 Feb; 710(1-2):121-4. PubMed ID: 8963650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles.
    Kreuter J; Ramge P; Petrov V; Hamm S; Gelperina SE; Engelhardt B; Alyautdin R; von Briesen H; Begley DJ
    Pharm Res; 2003 Mar; 20(3):409-16. PubMed ID: 12669961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of apolipoproteins on dalargin transport across the blood-brain barrier.
    Shamenkov DA; Petrov VE; Alyautdin RN
    Bull Exp Biol Med; 2006 Dec; 142(6):703-6. PubMed ID: 17603675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of poly(butylcyanoacrylate) nanoparticles with the blood-brain barrier in vivo and in vitro.
    Alyaudtin RN; Reichel A; Löbenberg R; Ramge P; Kreuter J; Begley DJ
    J Drug Target; 2001 Jun; 9(3):209-21. PubMed ID: 11697206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanoparticle technology for delivery of drugs across the blood-brain barrier.
    Schroeder U; Sommerfeld P; Ulrich S; Sabel BA
    J Pharm Sci; 1998 Nov; 87(11):1305-7. PubMed ID: 9811481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier.
    Kreuter J; Shamenkov D; Petrov V; Ramge P; Cychutek K; Koch-Brandt C; Alyautdin R
    J Drug Target; 2002 Jun; 10(4):317-25. PubMed ID: 12164380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double-coated poly (butylcynanoacrylate) nanoparticulate delivery systems for brain targeting of dalargin via oral administration.
    Das D; Lin S
    J Pharm Sci; 2005 Jun; 94(6):1343-53. PubMed ID: 15858853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circadian phase-dependent antinociceptive reaction in mice determined by the hot-plate test and the tail-flick test after intravenous injection of dalargin-loaded nanoparticles.
    Ramge P; Kreuter J; Lemmer B
    Chronobiol Int; 1999 Nov; 16(6):767-77. PubMed ID: 10584177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity.
    Olivier JC; Fenart L; Chauvet R; Pariat C; Cecchelli R; Couet W
    Pharm Res; 1999 Dec; 16(12):1836-42. PubMed ID: 10644071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Body distribution of 3H-labelled dalargin bound to poly(butyl cyanoacrylate) nanoparticles after i.v. injections to mice.
    Schroeder U; Schroeder H; Sabel BA
    Life Sci; 2000; 66(6):495-502. PubMed ID: 10794066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of oral dalargin-loaded nanoparticle delivery across the blood-brain barrier.
    Schroeder U; Sommerfeld P; Sabel BA
    Peptides; 1998; 19(4):777-80. PubMed ID: 9622035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved brain uptake and pharmacological activity of dalargin using a peptide-vector-mediated strategy.
    Rousselle C; Clair P; Smirnova M; Kolesnikov Y; Pasternak GW; Gac-Breton S; Rees AR; Scherrmann JM; Temsamani J
    J Pharmacol Exp Ther; 2003 Jul; 306(1):371-6. PubMed ID: 12682214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro release performance and analgesic activity of endomorphin-1 loaded nanoparticles.
    Liu H; Ni J; Wang R
    Pharmazie; 2006 May; 61(5):450-2. PubMed ID: 16724544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles.
    Wilson B; Samanta MK; Santhi K; Kumar KP; Paramakrishnan N; Suresh B
    Eur J Pharm Biopharm; 2008 Sep; 70(1):75-84. PubMed ID: 18472255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles.
    Alyautdin RN; Petrov VE; Langer K; Berthold A; Kharkevich DA; Kreuter J
    Pharm Res; 1997 Mar; 14(3):325-8. PubMed ID: 9098875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a chitosan-based nanoparticle formulation for delivery of a hydrophilic hexapeptide, dalargin.
    Chen Y; Siddalingappa B; Chan PH; Benson HA
    Biopolymers; 2008; 90(5):663-70. PubMed ID: 18655140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of particle size on transport of methotrexate across blood brain barrier by polysorbate 80-coated polybutylcyanoacrylate nanoparticles.
    Gao K; Jiang X
    Int J Pharm; 2006 Mar; 310(1-2):213-9. PubMed ID: 16426779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Molecular mechanisms of antioxidant action of dalargin on the liver in experimental cholestasis].
    Korotkina RN; Fomchenkov EP; Andreev VI; Smirnova VI; Karelin AA
    Biull Eksp Biol Med; 1992 Jan; 113(1):38-40. PubMed ID: 1391860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.